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INTRODUCTION
Prostate cancer is driven by the androgen-receptor (AR) signaling axis, including the terminal phase of the disease, metastatic castration-resistant prostate cancer (mCRPC). This AR addiction is the basis of numerous AR-targeted therapies for mCRPC that prolong survival and improve quality of life (1, 2) .
Given the central role the AR axis has in mCRPC and its treatment, there is a pressing need to credential non-invasive biomarkers capable of monitoring the pharmacologic targeting and effect of these drugs. 18 F-fluorodihydrotestosterone ( 18 F-FDHT) is a radiolabeled analogue of dihydrotestosterone, the primary ligand of the AR, which offers an innovative way of directly imaging the primary molecular engine of CRPC with positron emission tomography/computed tomography (PET/CT).
Preliminary studies using 18 F-FDHT PET/CT in patients with CRPC have demonstrated safety, feasibility, favorable pharmacokinetic properties, accuracy at identifying tumor localizations, and associations with survival (3) (4) (5) (6) (7) . Furthermore, 18 F-FDHT was instrumental for demonstrating AR targeting in the early-phase clinical trials of enzalutamide and apalutamide, two AR-directed therapies that have demonstrated substantial clinical activity in mCRPC (8, 9) . This international collaboration was undertaken to assess the repeatability and reproducibility of 18 F-FDHT uptake measures, a crucial component of biomarker development (10, 11) . Repeatability is defined as the measurement precision under a set of repeatability conditions (e.g., repeated scans within one subject) and reproducibility as the measurement precision under a set of different conditions in similar subjects (e.g., different locations, operators, readers) (12, 13) .
The aim of this study was to prospectively assess repeatability and reproducibility of whole-body 18 F-FDHT uptake metrics of mCRPC metastases.
MATERIALS AND METHODS
Patients were recruited prospectively from three tertiary academic centers:
Memorial Sloan Kettering Cancer Center (U.S.A), VU University Medical Center (Netherlands), and Austin Health (Australia). Each site opened its own study and managed the regulatory requirements specific to each institution and country. The trials, by prospective intent, were to collect and combine data under a predefined statistical plan. The lead site (Memorial Sloan Kettering) holds a US Food and Drug Administration Investigational New Drug application for 18 F-FDHT (#66115), and provided letters of cross-reference to facilitate submission for regulatory approval for the other sites. The institutional review boards of each center approved the study and all patients provided written informed consent prior to inclusion. The clinicaltrials.gov identifier is NCT00588185 (this number applies only to Memorial Sloan Kettering, the only US-based site).
Patient Eligibility and Study Design
Eligibility criteria included pathologically proven mCRPC, castrate serum testosterone (≤ 50 ng/dL), ≥ 4 weeks since their last anti-cancer pharmacologic therapy, and progressive disease based on a rise in PSA measured by Response Evaluation Criteria in Solid Tumors 1.1 imaging evidence of progressive disease and/or ≥ 2 new metastatic lesions on bone scan not attributable to the flair phenomenon.
Patients without surgical or medical castration remained on androgen depletion therapy with gonadotropin-releasing hormone analogues/inhibitors. Patients on enzalutamide or other anti-androgens within four weeks were excluded, as this therapy directly competes with 18 F-FDHT uptake. The design included means to evaluate the effect of time between the test and re-test 18 F-FDHT injections on the uptake measurements. Up to three cohorts were planned for test/re-test scans (cohort 1: days 1 and 2; cohort 2: days 1 and 8; and cohort 3: days 1 and 22). Initially, patients would be studied in cohort 1. If unstable test/re-test FDHT uptake (defined as a relative difference > 0.15) was present in ≥ 5 patients at any time, the study would proceed to the subsequent cohort. However, as a relative difference > 0.15 was not observed in 
Image Acquisition
Images were acquired using a GE690 or GE710 (General Electric, USA) or Philips Gemini TF64 or Philips Ingenuity TF128 (Philips Medical Systems, The Netherlands/USA) PET/CT scanner. For each scan, a low-dose CT (120-140 kV, 80 mA) was performed, followed by a dynamic 30-min PET scan over the thorax after 
Data Management and Analysis
The Clinical Trials Network from the Society of Nuclear Medicine and Molecular Imaging provided both centralized data management and access to Imagys ® , a webbased Imaging Clinical Trial management system by Keosys (Saint-Herblain, France), for secure uploading, storage, downloading, and analysis of images.
All images were evaluated independently by a dually trained radiologist/ nuclear medicine physician and a nuclear medicine resident (8 and 3 years experience in PET/CT, respectively). Lesions were considered suspicious for metastases when uptake was visually higher than blood pool activity measured in the thoracic aorta or background tissue specific to the site of the lesion and separate from known physiologic uptake (blood pool, biliary, urinary, and gastrointestinal tracts). Lesion type (bone, nodal, or other soft tissue) and anatomic site (grouped into 11 regions for bone, 11 regions for nodes, and 10 regions for other soft tissue) were recorded (Supplemental Figure 7 .1). The most visually avid 18 F-FDHT-avid lesion in each predefined anatomic region was delineated and a volume of interest generated semi-automatically using a 50% isocontour of SUVmax corrected for local background. The following 18 F-FDHT uptake metrics were recorded: SUVmax, SUVpeak (1.2 cm 3 spherical region positioned within the lesion to maximize its mean value), and SUVmean (all voxels within the lesion) corrected for body weight. Additionally, these metrics were normalized to the area under the parent plasma activity concentration curve (AUC) at 30 min (SUVAUC,PP) (14) .
Androgen receptor-positive tumor volume (ARTV, derived using a 50% threshold of SUVmax corrected for local background) and total lesion uptake (TLU, defined as SUVmean × ARTV) of 18 F-FDHT were calculated.
Statistical Analysis
Repeatability and inter-observer reproducibility were determined by calculating the relative absolute difference in 18 F-FDHT uptake metrics between the test and re-test scans, and between the values of the uptake metrics measured by the two readers. The relative absolute difference was computed as:
If no lesion was identified in a patient, the absolute change was set to zero but was not taken into account when calculating quantitative repeatability coefficients (RCs). The RC was calculated as 1.96 x standard deviation (SD) of the relative absolute differences per lesion and per patient for all uptake metrics. Normality was evaluated visually using a quantile-quantile plot and histogram analyses. Significance of differences in uptake metrics between the two scans and between the two readers was assessed using a paired t-test. To assess differences in RCs, Levene's test was performed; differences were deemed significant if p < 0.05. Linear regression analyses, intraclass correlation coefficients (ICC), and Bland-Altman plots were used to evaluate repeatability. Additionally, the coefficient of variation (COV) and ICC were used to investigate inter-observer reproducibility.
Levene's test was performed to assess the effect of various lesion selection strategies on repeatability and reproducibility: lesions ≥ 4.2 mL (diameter ≥ 2 cm), SUV ≥ 4.0 g/mL, and up to the five most radiotracer-avid lesions, as suggested by the PET
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Response Criteria in Solid Tumors guidelines (15) . In addition, the uptake values of these five individual target lesions were averaged per patient to obtain mean uptake values. A post-hoc linear regression analysis was performed to evaluate the influence of PSA levels, Gleason score, weight, and differences in total injected activity and uptake time between both scans on a per-patient basis. Based on previous reports on repeatability of FDG uptake in malignant tumors, ≤ 30% variability between the test and re-test was considered acceptable (15, 16) . All statistical analyses were performed using SPSS 22.0 (SPSS, USA).
Additional details on study design, image acquisition and processing, and Radio-HPLC Analysis of FDHT Metabolism are available upon request.
RESULTS
Thirty-two patients were included. The minimum number of paired evaluations per patient (i.e., per the anatomic regions described in the Methods section) was 1; the maximum was 12. Five patients were excluded from the RC calculations, as no lesions were detected on PET. Overall, 27 patients with a total of 140 18 F-FDHT-avid lesions were evaluated. No significant differences in patient characteristics were observed between the test and re-test scans. The total injected activities at Center 2 were significantly lower than those of Centers 1 and 3; however, no systematic differences were found in the SUVs from Centers 1 and 3 (Tables 7.1 and 7. 2). 
Repeatability
The best repeatability of 18 F-FDHT PET/CT uptake metrics was found for SUV,
where the predefined threshold of variability ≤ 30% was met (Table 7 Assessing variability of the 18 F-FDHT uptake metrics on a per-patient basis improved repeatability of all uptake metrics (Table 7. 3) (Figure 7 .6). RCs of SUV decreased 6% on average, which was significant for SUVmax and SUVmean. The improvement of volumetric measures was larger, with changes in RCs of TLU and ARTV being 12.7 and 23.1%, respectively. This was mainly caused by a large decrease in variability of ARTV of Centers 2 and 3 after averaging the data. PSA level, Gleason score, weight, and age did not affect repeatability, nor did differences in total injected activity or uptake time post-injection between both scans (R 2 < 0.08) (Figure 7.7) . clinical trial and reported thresholds of 28%/32% decrease and 39%/47% increase in SUVmax/SUVpeak, respectively, to be most indicative of actual therapeutic effects (16) .
However, multiple technical and logistic factors can impact these measurements, including differences in volume of interest, delineation, magnitude of uptake metrics, and uptake time after IV injection, as well as difficulties related to adherence to protocol design in a multi-institutional setting (18, 19) . Similar studies in patients with prostate cancer have been conducted with other radiotracers. Variation coefficients of 14% and 7% were reported on 18 F-NaF PET/CT in patients with mCRPC for SUVmax and SUVmean, respectively (20) . In a study using 18 F-fluoromethylcholine in patients with mCRPC, repeatability coefficients ranging between 22-26% were reported for different SUV metrics (21) . Additionally, this study also reported that RCs of metabolically active tumor volume and TLU were significantly larger compared to those for SUV (36% and 33%, respectively). Other studies also using SUVmax-based thresholds showed similar results (22, 23) , yet a significant decrease in repeatability was seen when only lesions ≤ 4.2 mL were included in the analysis. Studies have also shown decreased variability when evaluating repeatability on a per-patient (as opposed to a per-lesion) basis (14, 21) .
Normalization to the Parent Plasma Input Curve
Two studies have shown a correlation (R 2 : 0.6-0.7) between non-linear regression analysis of dynamic 18 F-FDHT data and SUV (5, 14) . Additionally, preliminary results showed a near-perfect correlation when the SUV was normalized to the area under the parent plasma input curve (R 2 : 0.99). A potential advantage of normalization to the parent plasma input curves is that the uptake metrics are corrected for any 7 treatment-induced or other changes in the radiotracer's metabolism, albeit at the expense of an additional dynamic PET scan, venous blood samples, and metabolite analysis. Moreover, including an additional variable into uptake metric calculations can increase uncertainty (14, 21) , although in the present study, SUVAUC,PP did not significantly affect overall variability of any of the SUV metrics on a lesion level. One outlier was seen with unexplained large differences in whole blood activity concentrations between test and re-test scans, which could not be accounted for by sample measurement errors, suggesting the need for caution in case of response assessment.
Our study had limitations. To overcome possible confounders in our study, all lesions were delineated by two independent readers. For SUVmax and SUVpeak, reproducibility was nearly perfect and differences in SUVmean between readers were small. Moreover, differences in uptake time between the test and re-test scans did not affect repeatability, suggesting that the influence of this factor was minor. However, repeatability data from two readers are insufficient to make strong statements about agreement across a larger pool of readers and will require validation. Patients with CRPC often present with numerous metastatic lesions and, ideally, each lesion should be delineated and assessed. However, this is impractical in routine clinical scenarios and therefore we predefined anatomic regions. Yet, this still resulted in ≥ 10 evaluable regions in 20% of the patients. Several other (simpler) lesion selection criteria were also investigated; those regions did not result in a change in variability.
CONCLUSION
Metrics derived from 18 F-FDHT PET/CT show high repeatability and interobserver reproducibility. Amongst 18 F-FDHT uptake metrics, SUV had the best repeatability, and although ARTV and TLU showed good correlation, variability was higher.
SUPPLEMENTAL MATERIALS
Supplemental Table 7 .1: Overview of anatomical regions for evaluation of repeatability. 
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